Last updated on July 2019

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease_


Brief description of study

The name of this trial is MissionAD2. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for end points for the studies E2609-G000-301 (NCT02956486) and E2609-G000-302 (NCT03036280) will be pooled for a combined total of 1900 participants.

Clinical Study Identifier: NCT03036280

Find a site near you

Start Over

Eisai Trial Site 1

Shibuya-ku, Japan
2.41miles
  Connect »

Eisai Trial Site 1

Bunkyo-ku, Japan
2.9miles
  Connect »

Eisai Trial Site 2

Bunkyo-ku, Japan
2.9miles
  Connect »

Eisai Trial Site 3

Bunkyo-ku, Japan
2.9miles
  Connect »

Eisai Trial Site 1

Minato-ku, Japan
3.66miles
  Connect »

Eisai Trial Site 4

Bunkyo-ku, Japan
3.71miles
  Connect »

Eisai Trial Site 1

Nerima-Ku, Japan
4.1miles
  Connect »

Eisai Trial Site 1

Chuo-ku, Japan
4.16miles
  Connect »

Eisai Trial Site 1

Nerima-ku, Japan
5.97miles
  Connect »

Eisai Trial Site 1

Shinagawa-ku, Japan
6.03miles
  Connect »

Eisai Trial Site 2

Shinagawa-ku, Japan
6.03miles
  Connect »

Eisai Trial Site 1

Ota-ku, Japan
6.9miles
  Connect »

Eisai Trial Site 1

Koto-ku, Japan
7.48miles
  Connect »

Eisai Trial Site 1

Mitaka City, Japan
7.71miles
  Connect »

Eisai Trial Site 2

Ota-ku, Japan
7.78miles
  Connect »

Eisai Trial Site 1

Katsushika-ku, Japan
8.76miles
  Connect »